Your browser doesn't support javascript.
loading
Rate of progression of Guillain-Barré syndrome is not associated with the short-term outcome of the disease.
Arsenijevic, Mirjana; Berisavac, Ivana; Mladenovic, Branka; Stanarcevic, Predrag; Jovanovic, Dejana; Lavrnic, Dragana; Peric, Stojan.
  • Arsenijevic M; Neurology Clinic, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Dr Subotica 6, Belgrade, 11129, Serbia.
  • Berisavac I; Neurology Clinic, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Dr Subotica 6, Belgrade, 11129, Serbia.
  • Mladenovic B; Physical Medicine and Rehabilitation Clinic, Clinical Center of Serbia, Belgrade, Serbia.
  • Stanarcevic P; Neurology Clinic, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Dr Subotica 6, Belgrade, 11129, Serbia.
  • Jovanovic D; Neurology Clinic, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Dr Subotica 6, Belgrade, 11129, Serbia.
  • Lavrnic D; Neurology Clinic, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Dr Subotica 6, Belgrade, 11129, Serbia.
  • Peric S; Neurology Clinic, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Dr Subotica 6, Belgrade, 11129, Serbia. stojanperic@gmail.com.
Ir J Med Sci ; 190(1): 357-361, 2021 Feb.
Article en En | MEDLINE | ID: mdl-32666503
ABSTRACT

INTRODUCTION:

There are no many data on association between progression rate of Guillain-Barré syndrome (GBS) and disease outcome.

AIM:

The aim of our study was to analyze short-term outcome of GBS in relation to the rate of disease progression.

METHODS:

Our retrospective study included patients diagnosed with GBS in seven tertiary healthcare centers from 2009 to 2014. According to the rate of disease progression from onset of symptoms to the nadir, patients were divided in three groups rapid-onset GBS (nadir reached in maximum 48 h), gradual-onset (nadir reached in three to 14 days), and slow-onset (nadir in 15 to 28 days). GBS disability scale (GDS) was used to assess functional disability at nadir and on discharge.

RESULTS:

Among 380 patients included in the study, 24 (6.3%) patients had rapid-onset, 274 (72.1%) gradual-onset, and 82 (21.6%) slow-onset GBS. Time from the onset of the disease to the hospital admission was much shorter in faster-onset forms (3.0 ± 4.1 days in rapid-onset vs. 6.8 ± 9.5 days in gradual-onset and 21.0 ± 9.6 days in slow-onset GBS, p < 0.01). Preceding events were less commonly identified in slow-onset forms. Patients with rapid-onset GBS were more likely to have axonal variants (p < 0.05). All three groups of patients were treated in a similar way, and there were no differences in GDS score at nadir (p > 0.05) and on discharge (p > 0.05) and no differences in the duration of hospital stay.

CONCLUSION:

Faster progression of GBS does not imply a poorer short-term functional outcome of the disease.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Síndrome de Guillain-Barré Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Síndrome de Guillain-Barré Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Año: 2021 Tipo del documento: Article